Physician profile
Ryan Scovanner
NPI 1245967538
$9,338.58
in general payments reported to CMS, 2019-2025
33 companies · $3,491 in 2025
The $3,491 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $591 · 2023: $2,429 · 2024: $2,827 · 2025: $3,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,703 · Education: $44.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,702.88 |
| Education | $44.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,457.79 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,425.18 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.61 | 2022-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $515.46 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $494.50 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $457.09 | 2023-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $424.35 | 2023-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $288.46 | 2024-2025 | Voquezna |
| Pfizer INC. | $261.39 | 2022-2025 | |
| Madrigal Pharmaceuticals | $254.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $251.27 | 2022-2025 | |
| Lilly USA, LLC | $248.02 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $241.16 | 2022-2025 | Ocaliva |
| Vivus LLC | $199.62 | 2022-2025 | Qsymia |
| Celgene Corporation | $127.90 | 2022-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $115.04 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.57 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $99.44 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $98.79 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $61.94 | 2023 | Injectafer |
| Ardelyx, INC. | $60.96 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $60.95 | 2023-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $52.62 | 2023 | |
| Organon LLC | $45.24 | 2024-2025 | Hadlima, Renflexis |
| Sandoz INC. | $40.20 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $37.05 | 2023-2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $31.43 | 2023 | Rebyota |
| Amgen INC. | $25.11 | 2023 | Avsola, Amjevita |
| Exact Sciences Corporation | $21.00 | 2023 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $18.22 | 2023 | Esophyx |
| Stryker Corporation | $16.27 | 2025 | Neptune |
| Braintree Laboratories, INC. | $14.23 | 2025 | Sutab, Suflave |
| Novo Nordisk INC | $14.20 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Scovanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.